Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ENOV
Enovis Corporation (ENOV) P/E ratio
Enovis Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 117× (December 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 54.9× | (22.37%) |
| FY2020 | 70.8× | — |
| FY2019 | 0.0× | — |
| FY2018 | 10.2× | (45.28%) |
| FY2017 | 18.7× | (8.00%) |
| FY2016 | 20.4× | 106.64% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| AORT Artivion, Inc. compare | n/m |
| CBLL CeriBell, Inc. compare | n/m |
| IART Integra LifeSciences Holdings Corporation compare | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| ENOV Enovis Corporation | n/m |
| TNDM Tandem Diabetes Care, Inc. compare | n/m |
| BVS Bioventus Inc. compare | 16.4× |
| IRMD iRadimed Corporation compare | 48.5× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)